ORIGINAL RESEARCH article
Front. Nucl. Med.
Sec. Radiopharmacy and Radiochemistry
This article is part of the Research TopicInnovative Radiotracers in Neurodegenerative Studies: Implications and ApplicationsView all articles
Automated Radiosynthesis and Clinical Experience of [18F]SMBT-1 PET Imaging for In Vivo Evaluation of Reactive Astrocyte in Parkinson's Disease: A Pilot Study
Provisionally accepted- 1Chulabhorn Hospital, Bangkok, Thailand
- 2Tohoku Ika Yakka Daigaku, Sendai, Japan
- 3Tohoku Daigaku, Sendai, Japan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Neuroinflammation plays an important role in progression of Parkinson disease (PD). [18F]SMBT-1 is a promising novel radiotracer for in vivo evaluation of reactive astrogliosis. Methods: The automated radiosynthesis of [18F]SMBT-1 was optimized and performed production by using the Synthra RNplus synthesizer module, and the quality of the labeled tracer was evaluated. Total 5 participants, 2 PD and 3 Healthy Control were enrolled. Cognitive assessments were performed in all participants while H&Y scales and MDS-UPDRS were performed only in PD. All participants underwent [18F]SMBT-1 PET/MRI and [18F]FDOPA PET/CT within 2-week intervals. Demographic and imaging data were collected. The correlation between [18F]FDOPA uptake and [18F]SMBT-1 uptake was analyzed by Spearman's correlation. Results: [18F]SMBT-1 was successfully synthesized via nucleophilic substitution of a tosylate precursor, followed by a deprotection step. After purification and formulation, [18F]SMBT-1 was obtained with an average decay-corrected radiochemical yield of 36.56 ± 11.55% and molar activity as 396 Gbq/μmol at the end of synthesis (n = 7). Moderate PD defined by the [18F]FDOPA showed increased [18F]SMBT-1 in prefrontal cortex, temporal lobes, striatum, thalamus, pons, medullar, and midbrain while severe PD showed globally increased [¹⁸F]SMBT-1. Healthy control also showed globally increased [18F]SMBT-1 uptake. There was no significant correlation between the degree of [18F]FDOPA uptake and [18F]SMBT-1 uptake in any brain region. Conclusion: The automated radiosynthesis of [18F]SMBT-1 are suitable for routine production without any immediate complication reported after administration. Moderate PD shows decreased astrocyte function as they lose neuroprotective astrocytes while severe PD shows increased astrocyte function as increased neurotoxic astrocytes.
Keywords: [18F]SMBT-1, MAO-B, Reactive astrocyte, Neuroinflammation, PET, Parkinson's disease
Received: 03 Oct 2025; Accepted: 18 Nov 2025.
Copyright: © 2025 Kiatkittikul, Lerdsirisuk, Bhuthathorn, Choolam, Jantarato, Kongsakorn, Chintawan, Sringam, Fonghoi, Vanprom, Harada, Okamura, Furumoto and Promteangtrong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chetsadaporn Promteangtrong, chetsadaporn.pro@cra.ac.th
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
